Pluronic® F127-based systemic vaccine delivery systems

被引:68
作者
Coeshott, CM
Smithson, SL
Verderber, E
Samaniego, A
Blonder, JM
Rosenthal, GJ
Westerink, MAJ
机构
[1] RxKinetix Inc, Louisville, CO 80027 USA
[2] Med Coll Ohio, Dept Med, Toledo, OH USA
[3] Med Coll Ohio, Dept Pathol, Toledo, OH USA
关键词
pluronic; adjuvant; vaccine delivery;
D O I
10.1016/j.vaccine.2003.11.064
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have developed a vaccine delivery system based on the non-ionic block copolymer, Pluronic(R) F127 (F127), combined with selected immunomodulators. F127-based matrices are characterized by a phenomenon known as reverse thermogelation, whereby the formulation undergoes a phase transition from liquid to gel upon reaching physiological temperatures. Protein antigens (tetanus toxoid (TT), diphtheria toxoid (DT) and anthrax recombinant protective antigen (rPA)) were formulated with F127 in combination with CpG motifs or chitosan, as examples of immunomodulators, and were compared to more traditional adjuvants in mice. IgG antibody responses were significantly enhanced by the F127/CpG and F127/chitosan combinations compared to antigens mixed with CpGs or chitosan alone. In addition, the responses were significantly greater than those elicited by aluminum salts. Furthermore, the functional activity of these antibodies was demonstrated using either in vivo tetanus toxin challenge or an anthrax lethal toxin neutralization assay. These studies suggest that a block-copolymer approach could enhance the delivery of a variety of clinically useful antigens in vaccination schemes. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2396 / 2405
页数:10
相关论文
共 48 条
[1]   Immunization of mice with DNA encoding fragment C of tetanus toxin [J].
Anderson, R ;
Gao, XM ;
Papakonstantinopoulou, A ;
Fairweather, N ;
Roberts, M ;
Dougan, G .
VACCINE, 1997, 15 (08) :827-829
[2]   Factors affecting short-term and long-term stabilities of proteins (Reprinted from Advanced Drug Delivery Reviews, vol 9, pg 201-237, 1992) [J].
Arakawa, T ;
Prestrelski, SJ ;
Kenney, WC ;
Carpenter, JF .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 46 (1-3) :307-326
[3]   Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens [J].
Bacon, A ;
Makin, J ;
Sizer, PJ ;
Jabbal-Gill, I ;
Hinchcliffe, M ;
Illum, L ;
Chatfield, S ;
Roberts, M .
INFECTION AND IMMUNITY, 2000, 68 (10) :5764-5770
[4]   FIELD-EVALUATION OF A HUMAN ANTHRAX VACCINE [J].
BRACHMAN, PS ;
FEKETY, FR ;
GOLD, H ;
WERRIN, M ;
INGRAHAM, NR ;
PLOTKIN, SA .
AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1962, 52 (04) :632-+
[5]   Improvement of receptor-mediated gene delivery to HepG2 cells using an amphiphilic gelling agent [J].
Cho, CW ;
Cho, YS ;
Lee, HK ;
Yeom, YI ;
Park, SN ;
Yoon, DY .
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2000, 32 :21-26
[6]   CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies [J].
Chu, RS ;
McCool, T ;
Greenspan, NS ;
Schreiber, JR ;
Harding, CV .
INFECTION AND IMMUNITY, 2000, 68 (03) :1450-1456
[7]   CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi [J].
Corral, RS ;
Petray, PB .
VACCINE, 2000, 19 (2-3) :234-242
[8]  
Davis HL, 1998, J IMMUNOL, V160, P870
[9]   Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model [J].
Desai, SD ;
Blanchard, J .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (10) :1190-1195
[10]   In vitro evaluation of pluronic F127-based controlled-release ocular delivery systems for pilocarpine [J].
Desai, SD ;
Blanchard, J .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (02) :226-230